Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 189 participants.

Also called NCT01805830

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 189 participants (enrolled count) (from the registry)
Sponsor
  • Handok Inc. Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01805830
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01805830. Randomized; double masking; primary purpose treatment. Start 2012-05 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy
Acronym
T2DM
Intervention (Drug)
MP513
Intervention (Drug)
Placebo
Lead sponsor
Handok Inc. (class: industry)

Record details

Record id
cardio:ct-nct01805830
Content hash
a87fa478063c6a2fa4b4ea95b5820e478cc251d4767735a4fd0cf5127534232c